uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Antagonists of IGF: Vitronectin Interactions Inhibit IGF-I-Induced Breast Cancer Cell Functions
Queensland Univ Technol, Tissue Repair & Regenerat Program, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.;Univ Basel Hosp, Dept Biomed, Canc Immunol, Basel, Switzerland..
Queensland Univ Technol, Tissue Repair & Regenerat Program, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia..
Queensland Univ Technol, Tissue Repair & Regenerat Program, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia..
Queensland Univ Technol, Tissue Repair & Regenerat Program, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia..
Show others and affiliations
2016 (English)In: Molecular Cancer Therapeutics, ISSN 1535-7163, E-ISSN 1538-8514, Vol. 15, no 7, 1602-1613 p.Article in journal (Refereed) Published
Abstract [en]

We provide proof-of-concept evidence for a new class of therapeutics that target growth factor: extracellular matrix (GF: ECM) interactions for the management of breast cancer. Insulinlike growth factor-I (IGF-I) forms multiprotein complexes with IGF-binding proteins (IGFBP) and the ECM protein vitronectin (VN), and stimulates the survival, migration and invasion of breast cancer cells. For the first time we provide physical evidence for IGFBP-3: VN interactions in breast cancer patient tissues; these interactions were predominantly localized to tumor cell clusters and in stroma surrounding tumor cells. We show that disruption of IGF-I: IGFBP: VN complexes with L27-IGF-II inhibits IGF-I: IGFBP: VN-stimulated breast cancer cell migration and proliferation in two-and three-dimensional assay systems. Peptide arrays screened to identify regions critical for the IGFBP-3/-5: VN and IGF-II: VN interactions demonstrated IGFBP-3/-5 and IGF-II binds VN through the hemopexin-2 domain, and VN binds IGFBP-3 at residues not involved in the binding of IGF-I to IGFBP-3. IGFBP-interacting VN peptides identified from these peptide arrays disrupted the IGF-I: IGFBP: VN complex, impeded the growth of primary tumor-like spheroids and, more importantly, inhibited the invasion of metastatic breast cancer cells in 3D assay systems. These studies provide first-in-field evidence for the utility of small peptides in antagonizing GF: ECM-mediated biologic functions and present data demonstrating the potential of these peptide antagonists as novel therapeutics.

Place, publisher, year, edition, pages
2016. Vol. 15, no 7, 1602-1613 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-303393DOI: 10.1158/1535-7163.MCT-15-0907ISI: 000381087200017PubMedID: 27196774OAI: oai:DiVA.org:uu-303393DiVA: diva2:971775
Available from: 2016-09-19 Created: 2016-09-19 Last updated: 2016-09-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Söderberg, Ola
By organisation
Molecular toolsScience for Life Laboratory, SciLifeLab
In the same journal
Molecular Cancer Therapeutics
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 310 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf